Compare Bristol-Myers Squibb Co (BMY) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Abrdn Physical Platinum Shares ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.37 (market cap $116.30B), while Abrdn Physical Platinum Shares ETF trades at $14.9. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Abrdn Physical Platinum Shares ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| BMY | PPLT | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $62.37 | $25.23 |
52-Week Low | $42.60 | $11.78 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
PPLT trades at $14.52, down 1.69% with a bearish technical outlook showing 15 sell signals versus 0 buy signals. The ETF recently underwent a 1:10 stock split effective May 18, 2026, which adjusted share count without changing the fund's underlying value. Platinum has underperformed other precious metals recently, creating potential catch-up trade opportunities according to market commentary.
The outlook remains cautious as platinum lags gold's rally, though some analysts see long-term potential. Key risks include precious metals volatility and correlation dynamics. Recent downgrades to 'Hold' suggest limited near-term upside after PPLT's 84-100% returns over the past year, requiring careful entry timing for new positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
